03.05.2022 HAEMATO AG  DE000A289VV1

DGAP-Adhoc: HAEMATO AG: Dividend of EUR 1.10


 

DGAP-Ad-hoc: HAEMATO AG / Key word(s): Dividend
HAEMATO AG: Dividend of EUR 1.10

03-May-2022 / 14:56 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


______________________________________________________________________________

HAEMATO AG: Dividend of EUR 1.10

Berlin, May 3, 2022 - At today's balance sheet meeting, the annual financial statements 2021 of HAEMATO AG, which were issued with an unqualified audit certificate, were adopted. The preliminary figures were confirmed. The Executive Board and Supervisory Board will propose a dividend of EUR 1.10 per dividend-bearing share to the Annual General Meeting to be held in presence on July 12, 2022.

About HAEMATO:

HAEMATO AG was founded in 1993 and is a pharmaceutical company focusing on the trade of high-priced specialty pharmaceutical drugs (with the therapeutic focus on oncology, HIV, rheumatology and other chronic diseases) as well as the development and distribution of medical products and private brands, especially in the area of "Lifestyle & Aesthetics". HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. For further information, please visit www.haemato.de.




Contact:
HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70
[email protected]

03-May-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: HAEMATO AG
Lilienthalstraße 5c
12529 Schönefeld
Germany
Phone: +49 (0)30 897 30 86 70
Fax: +49 (0)30 897 30 86 79
E-mail: [email protected]
Internet: www.haemato.ag
ISIN: DE000A289VV1
WKN: A289VV
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 1342367

 
End of Announcement DGAP News Service

1342367  03-May-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1342367&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 289,86 274,12 197,84 238,33 285,04 248,14 282,00
EBITDA1,2 11,27 9,96 1,90 3,31 12,64 9,66 12,40
EBITDA-Marge3 3,89 3,63 0,96 1,39 4,43 3,89
EBIT1,4 9,42 8,50 -18,68 1,63 11,16 8,30 11,40
EBIT-Marge5 3,25 3,10 -9,44 0,68 3,92 3,35 4,04
Jahresüberschuss1 6,98 6,28 -1,17 -4,83 6,53 8,19 6,90
Netto-Marge6 2,41 2,29 -0,59 -2,03 2,29 3,30 2,45
Cashflow1,7 -8,35 0,56 -2,76 14,67 14,05 19,73 0,00
Ergebnis je Aktie8 3,20 2,70 -0,50 -1,02 1,35 1,57 1,34
Dividende8 3,00 1,00 0,00 0,00 1,10 1,20 3,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Harry Haseloff

INVESTOR-INFORMATIONEN
©boersengefluester.de
Haemato
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A289VV 17,200 - 89,94
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
10,75 15,58 0,68 8,65
KBV KCV KUV EV/EBITDA
0,63 4,56 0,36 7,12
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
1,20 0,70 4,07 18.07.2023
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
31.05.2023 31.08.2023 16.11.2023 17.05.2023
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-12,76% -21,22% -35,34% -4,44%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu HAEMATO AG  ISIN: DE000A289VV1 können Sie bei EQS abrufen


Gesundheit , A289VV , HAEK , XETR:HAEK